Figure 9Relative changes in gene expression for SARS-CoV-2 infections and associated modulation in coagulation and immune responses are increased after SARS-CoV-2 MA30 infection in lung tissues (SARSCoV-2 MA30 infection - N = 18 mice 4 days follow up; N = 20 mice 7 days follow up; Uninfected mice - N = 2). PEGSerp-1 treatment significantly modified gene expression for uPAR A-C Gene expression for PEGserp-1 targets are increased after infection and modified by PEGSerp-1 treatments. uPA (A; p = 0.3263), PAI-1 (B; p < 0.0001) and uPAR (C; p < 0.0001) were increased in infected mouse lung extracts at 4 days follow up when compared to uninfected lungs with SARS-CoV-2 MA30 infection. PEG Serp-1 treatment produced a significant increase in uPAR (C; p < 0.0157). Data information: N = 19 mice at 4 days follow up; N = 20 mice at 7 days follow up. ANOVA indicated by line at top with subgroup analyses below; infected mice - blue circles Saline, red circle PEGSerp-1 treatments, green circle uninfected mice).Relative changes in gene expression for SARS-CoV-2 infections and associated modulation in coagulation and immune responses are increased after SARS-CoV-2 MA30 infection in lung tissues (SARSCoV-2 MA30 infection - N = 18 mice 4 days follow up; N = 20 mice 7 days follow up; Uninfected mice - N = 2). PEGSerp-1 treatment significantly modified gene expression for complement pathways. D-F Complement pathways genes encoding C3 (D; p < 0.0021), C5 (E; p < 0.001) and C1INh (F; p < 0.0008) were also significantly increased with infection. PEG Serp-1 treatment produced a borderline decrease in C5 (E; p = 0.0623) and a significant increase in C1Inh (F; p < 0.0309). Data information: N = 19 mice at 4 days follow up; N = 20 mice at 7 days follow up. ANOVA indicated by line at top with subgroup analyses below; infected mice - blue circles Saline, red circle PEGSerp-1 treatments, green circle uninfected mice).Relative changes in gene expression for SARS-CoV-2 infections and associated modulation in coagulation and immune responses are increased after SARS-CoV-2 MA30 infection in lung and heart tissues (SARSCoV-2 MA30 infection - N = 18 mice 4 days follow up; N = 20 mice 7 days follow up; Uninfected mice - N = 2). PEGSerp-1 treatment significantly modified gene expression for complement pathways. G-I At 7 days follow up, relative gene expression is no longer increased for C1Inh with PEGSerp-1 treatment in MA30 infected mouse lungs (G; p = 0.5956), but C1Inh was significantly increased in myocardial extracts with PEGSerp-1 treatment at 7 days (H; p < 0.0419). C5 was not significantly increased with infection (I; p = 0.1601) Data information: N = 19 mice at 4 days follow up; N = 20 mice at 7 days follow up. ANOVA indicated by line at top with subgroup analyses below; infected mice - blue circles Saline, red circle PEGSerp-1 treatments, green circle uninfected mice).Relative changes in gene expression for SARS-CoV-2 infections and associated modulation in coagulation and immune responses are increased after SARS-CoV-2 MA30 infection in lung and heart tissues (SARSCoV-2 MA30 infection - N = 18 mice 4 days follow up; N = 20 mice 7 days follow up; Uninfected mice - N = 2). PEGSerp-1 treatment significantly modified gene expression for uPAR J-L PAI-1 gene expression was not increased in lung extracts with PEGSerp-1 treatment at 7 days follow up in MA30 infected mouse lungs (J; p = 0.2403), but PAI-1 expression was significantly increased at 7 days follow up in heart extracts (K; p < 0.0454). uPAR was not significantly increased in lung extracts at 7 days follow up (p = 0.1514). A time course for gene expression illustrates a peak time for changes in C1Inh gene expression demonstrates greater changes at 4 days when compared to day2 and day15 (L). Data information: N = 19 mice at 4 days follow up; N = 20 mice at 7 days follow up. ANOVA indicated by line at top with subgroup analyses below; infected mice - blue circles Saline, red circle PEGSerp-1 treatments, green circle uninfected mice).